Gaurav Aggarwal
Managing Director @ Vivo Capital
Menlo Park, United States
Gaurav Aggarwal is a seed investor at Vivo Capital in Menlo Park focused on Health Care and Biotechnology. Gaurav Aggarwal is the Managing Director of Vivo Capital. He received his M.D. from Columbia University, College of Physicians and Surgeons, and his B.S. in Agricultural Economics from Cornell University.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Gaurav Aggarwal invests in
Stages Gaurav Aggarwal invests in
Countries Gaurav Aggarwal invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (83%)
- Biotechnology 5 (83%)
- Medical 3 (50%)
- Pharmaceutical 3 (50%)
- Therapeutics 2 (33%)
Stage
- Seed 1 (17%)
- Series B 1 (17%)
- Series C 1 (17%)
- Series D 1 (17%)
- Private Equity 1 (17%)
Country
- United States 5 (83%)
- China 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M / Series B / Jan 08, 2026 | ||
| Serán is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. | $200M / Private Equity / Sep 17, 2024 | ||
| Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’sSyndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease.Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California. | $30M / Post-IPO Equity / Mar 06, 2023 | ||
Visirna Therapeutics
|
Visirna Therapeutics to develop and commercialize RNAi therapeutics targeting cardiovascular and metabolic diseases. | $60M / Seed / Apr 25, 2022 | |
| Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardivedyskinesia, and Tourette syndrome, as well as other orphan indications. | $25M / Series D / Nov 08, 2012 | ||
| NextWave Pharmaceuticals, a Cupertino, CA-based pharmaceutical company that develops and commercializes products utilizing proprietary drug delivery technology. | $45M / Series C / Jan 11, 2011 |
Co-Investors
About Vivo Capital
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Vivo Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Gaurav Aggarwal
Managing Director
|
|||
Michael Chang
Managing Partner
|
|||
Shan Fu
Managing Partner, Co-CEO, and CEO of Asia Pacific
|
|||
Chloe Zhang
Principal
|
|||
Edgar G. Engleman
Co - Founder & Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Gaurav Aggarwal invest in?
Gaurav Aggarwal invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gaurav Aggarwal?
Public channels for Gaurav Aggarwal include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gaurav Aggarwal last invest?
The most recent investment recorded for Gaurav Aggarwal closed in Jan 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
